围产期出血的诊断与治疗:跨学科工作组采用改良ACCORD方法达成的共识
该共识由跨学科工作组采用改良ACCORD方法制定,涵盖围产期出血的预防措施、 care组织及诊断治疗流程。推荐对存在PPH危险因素的产妇使用校准采血器监测出血量,高危者应在围产期重症监护中心分娩,产前治疗贫血(血红蛋白<110 g/L(早孕期)或<105 g/L(28周)时补铁)。所有阴道分娩在胎儿娩出及断脐后预防性使用缩宫素(强推荐),剖宫产者亦推荐使用宫缩剂预防PPH(强推荐),PPH高危剖宫产者可考虑单次TXA 1 g静脉注射(强推荐)。PPH发生后立即液体复苏,使用平衡晶体液(强推荐),未控制出血前收缩压目标80-90 mmHg(强推荐),液体复苏不能达标时尽早使用血管升压药(强推荐),纤维蛋白原<2 g/L和/或粘弹性方法提示功能性纤维蛋白原缺乏时补充至少4 g纤维蛋白原(强推荐),TXA初始1 g静脉注射尽快给药(强推荐),出血控制后不再继续TXA(强推荐),血浆15-20 mL/kg用于怀疑非纤维蛋白原缺乏所致凝血病(强推荐),并推荐最大程度纠正低体温、酸中毒和离子钙水平(强推荐)。
要点
- 所有阴道分娩在胎儿娩出及断脐后预防性使用宫缩剂(首选缩宫素)以降低PPH风险(强推荐)。
- PPH初始TXA 1 g静脉注射尽快给药,出血持续且证实或高度怀疑纤溶亢进时最早30分钟后可重复同剂量;出血控制后不再继续TXA(强推荐)。
- 纤维蛋白原降至<2 g/L和/或粘弹性方法检测功能性纤维蛋白原缺乏和/或临床合理怀疑纤维蛋白原缺乏时,初始补充至少4 g纤维蛋白原(强推荐)。
- 未控制出血前收缩压目标80-90 mmHg(强推荐);液体复苏不能达标时尽早使用血管升压药(强推荐);初始液体复苏使用平衡晶体液(强推荐)。
- 每个产科单位应确保24/7血液制品即时可用,初始确保4单位血浆(优先去污剂处理血浆)、4单位红细胞和6 g纤维蛋白原,纤维蛋白原最低储备8 g且1小时内可追加8 g(良好临床实践)。
适用人群与场景
- 存在PPH危险因素的产妇(如胎盘植入谱系疾病或需要血液科会诊的血液系统疾病)应在围产期重症监护中心或围产期中间监护中心分娩(良好临床实践)。
- 所有阴道分娩和剖宫产分娩的产妇均为预防性使用宫缩剂的对象。
- PPH高危剖宫产产妇可考虑单次TXA 1 g静脉注射(强推荐)。
诊断标准与关键阈值
- 妊娠早期血红蛋白<110 g/L或妊娠28周血红蛋白<105 g/L时应补充铁剂(良好临床实践)。
- 纤维蛋白原水平降至<2 g/L和/或粘弹性方法检测到功能性纤维蛋白原缺乏和/或临床合理怀疑纤维蛋白原缺乏时,启动纤维蛋白原替代(强推荐)。
- 怀疑非纤维蛋白原缺乏所致凝血病和/或凝血试验异常且结果不能可靠识别主要凝血障碍机制时,使用血浆15-20 mL/kg(强推荐)。
- 未控制出血前收缩压目标范围80-90 mmHg(强推荐)。
处置流程与药物剂量
- 所有阴道分娩在胎儿娩出及断脐后预防性使用宫缩剂,首选缩宫素(强推荐);剖宫产分娩后亦推荐使用宫缩剂预防PPH(强推荐)。
- PPH高危产妇可考虑使用卡贝缩宫素(弱推荐)。
- PPH高危剖宫产产妇推荐单次TXA 1 g静脉注射(强推荐);产品说明书未明确剖宫产前使用TXA,近期Meta分析指出最常见剂量为1 g静脉注射。
- 发现子宫张力减退或收缩乏力时使用结构化流程(良好临床实践);有血管内介入条件的科室,在临床情况允许时建议(弱推荐)优先考虑放射介入方法(选择性盆腔动脉栓塞)。
- 所有PPH阶段推荐输血前检查,除标准实验室检查外优先使用即时检验方法尤其是粘弹性方法评估凝血状态(良好临床实践)。
- PPH发生后立即液体复苏,初始使用平衡晶体液(强推荐);晶体液未达到或未达到血流动力学复苏目标且液体缺失持续时,建议(弱推荐)考虑使用含明胶的合成胶体。
- 未控制出血前收缩压目标80-90 mmHg(强推荐);持续液体复苏不能达到目标动脉血压时尽早使用血管升压药(强推荐)。
- TXA初始剂量1 g静脉注射,PPH发生后尽快给药;出血持续且证实纤溶亢进和/或当前临床高度怀疑纤溶亢进时,最早30分钟后可重复相同剂量(强推荐);出血控制后不推荐继续使用TXA(强推荐)。
红旗征与不能漏的情况
- 子宫张力减退或收缩乏力(需按结构化流程处理)(良好临床实践)。
- PPH标准治疗无效的凝血病(推荐与血液科合作)(良好临床实践)。
- 低体温、酸中毒和离子钙异常(需最大程度纠正)(强推荐)。
研究设计与关键结果
- 该共识由跨学科工作组采用改良ACCORD方法制定,包含预防措施与流程、 care组织、PPH诊断与治疗流程三部分推荐。
- 推荐对存在PPH危险因素的产妇使用校准采血器或等效设备监测产程中出血量(良好临床实践)。
- 推荐对有显著PPH危险因素(如胎盘植入谱系疾病或需要血液科会诊的血液系统疾病)的产妇在围产期重症监护中心或围产期中间监护中心分娩(良好临床实践)。
- 推荐对PPH高危患者在分娩前适当时间与多学科团队共同制定诊疗计划(良好临床实践)。
- 推荐产前治疗贫血,妊娠早期血红蛋白<110 g/L或28周<105 g/L时补充铁剂(良好临床实践);口服铁剂无反应且铁缺乏性贫血者可考虑肠外补铁(弱推荐),妊娠终止后应尽快明确贫血原因。
- 婴儿适应良好时,不推荐在1分钟内结扎脐带(强推荐)。
- 第三产程未积极管理时,建议(弱推荐)由合格医护人员考虑子宫按摩和受控脐带牵引以缩短第三产程并减少阴道分娩失血量。
- 每个设有妇产科的医疗机构应有PPH管理方案(危机行动方案),明确危机团队成员(非医疗人员、产科医生、麻醉医生、血液科医生等)的组织和专业角色及PPH患者救治的最低设备范围(良好临床实践)。
证据类型、等级与局限
- 证据类型:跨学科工作组共识,采用改良ACCORD方法制定。
- 推荐强度标签:强推荐(Strong recommendation)、弱推荐(Weak recommendation)、良好临床实践(Good Clinical Practice)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 所有阴道分娩在胎儿娩出及断脐后应预防性使用宫缩剂(首选缩宫素),剖宫产分娩后亦应使用宫缩剂预防PPH(强推荐)。
- PPH初始TXA 1 g静脉注射应尽快给药,出血持续且证实或高度怀疑纤溶亢进时最早30分钟后可重复同剂量;出血控制后不推荐继续使用TXA(强推荐)。
- 未控制出血前收缩压目标80-90 mmHg,液体复苏不能达标时尽早使用血管升压药(强推荐)。
- 纤维蛋白原<2 g/L和/或粘弹性方法提示功能性纤维蛋白原缺乏和/或临床合理怀疑纤维蛋白原缺乏时,初始补充至少4 g纤维蛋白原(强推荐)。
- 推荐使用粘弹性方法(ROTEM、TEG)识别PPH凝血障碍类型并指导靶向治疗(强推荐)。
- 推荐早期启动所有措施预防低体温并维持正常体温,最大程度纠正低体温、酸中毒和离子钙水平(强推荐);输注血液制品时监测并维持离子钙在正常范围,优先使用氯化钙纠正(强推荐)。
- 有血管内介入条件的科室,临床情况允许时建议(弱推荐)优先考虑选择性盆腔动脉栓塞治疗子宫张力减退或收缩乏力所致PPH。
- 每个设有妇产科的医疗机构应有PPH管理方案并定期(至少每年一次)进行危机模拟训练和质量指标评估(良好临床实践)。
指南或共识出处
- 指南名称:围产期出血的诊断与治疗:跨学科工作组采用改良ACCORD方法达成的共识(Diagnosis and treatment of peripartum haemorrhage, consensus of the interdisciplinary working group by the modified ACCORD method)。
- 发布机构:跨学科工作组(interdisciplinary working group)。
- 期刊:Ceska Gynekol。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
of recommendations Preventive measures and procedures We recommend monitoring of blood loss in women with risk factors for PPH during labor using calibrated blood collectors or their equivalents. (Good Clinical Practice) We recommend that women with significant risk factors for PPH (e.g., placenta acrreta spectrum or hematologic disorders requiring consultative hematologic care) deliver in a perinatal intensive care center or perinatal intermediate care center. (Good Clinical Practice) We recommend formulating a plan of care in collaboration with a multidisciplinary team at a reasonable time prior to delivery for patients at high risk of PPH. (Good Clinical Practice) We recommend treating anemia antepartally. Pregnant women should be given iron supplements if the haemoglobin level falls to < 110 g/L in the 1st trimester or < 105 g/L at 28 weeks of pregnancy. (Good Clinical Practice) We suggest considering parenteral iron administration in women with sideropenic anemia unresponsive to oral iron supplementation. The cause of anemia should be identified as soon as possible after termination of pregnancy. (Weak recommendation) If the baby adapts well, we do not recommend cord ligation in less than 1 min. (Strong recommendation) In all vaginal deliveries, we recommend prophylactic administration of uterotonics in the third postpartum period after the delivery of the baby and cord ligation to reduce the risk of PPH. The first-choice drug is oxytocin. (Strong recommendation) If the third stage of labor has not been actively managed, we suggest that uterine massage and controlled umbilical cord traction be considered to shorten the duration of the third stage of labor and to reduce blood loss during vaginal delivery, if performed by a qualified healthcare professional. (Weak recommendation) We recommend the administration of uterotonics to prevent the development of PPH in women after the delivery of a child by caesarean section and umbilical cord ligation. (Strong recommendation) We suggest considering carbetocin administration in women at increased risk of PPH. (Weak recommendation) We recommend a single-dose administration of tranexamic acid (TXA) in women at increased risk of PPH undergoing a caesarean section. Clinical note: The use of TXA prior to the caesarean section is not explicitly stated in the product's SPC. A recent meta-analysis states the most common dosage to be 1 g i.v. (Strong recommendation) Organization of care We recommend that every health care facility with an OB/GYN unit should have the PPH management protocol (guided document is not specific or really used at all, I am not sure if my suggestion is sufficient) defining the organizational and professional procedure for PPH situations. (Good Clinical Practice) We recommend that the PPH management protocol (i.e. the crisis action plan) should clearly define the organizational and professional roles of the individual members of the crisis team in the event of PPH (non-medical staff), obstetrician, anesthetist, hematologist, etc.) and define the minimum scope of equipment for the care of patients with PPH. (Good Clinical Practice) We recommend regular simulation training of PPH crisis by the entire crisis team with a subsequent debriefing or its formalized equivalent. (Good Clinical Practice) We recommend defining quality indicators for the diagnosis and treatment of PPH and their formalized evaluation at regular intervals, at least once a year. (Good Clinical Practice) Diagnostic and treatment procedure at PPH When hypotonia or atony of the uterus is found, we recommend using a structured procedure. (Good Clinical Practice) At departments with an option of endovascular interventions, we suggest considering the preferential use of radiological interventional methods (selective pelvic artery embolization) in cases of PPH due to uterine hypotonia or atony, if the current clinical context allows it. (Weak recommendation) For all stages of PPH development, we recommend a pre-transfusion examination. In addition to standard laboratory tests, point-of-care-testing methods, especially viscoelastic methods, are preferred to assess the current coagulation status. (Good Clinical Practice) Each obstetric unit should ensure a sufficient stock of blood products and blood derivatives for their immediate availability 24/7 in collaboration with the transfusion department and the inpatient pharmacy. In case of PPH development, we recommend securing initial availability of 4 units of plasma (solvent/detergent-treated plasma is preferred), 4 units of erythrocytes and 6 g of fibrinogen. We consider 8 g to be a minimum supply of fibrinogen and additional 8 g should be available within 1 h. (Good Clinical Practice) We recommend the initiation of immediate fluid resuscitation in all patients with PPH. We recommend the use of balanced crystalloid solutions to initiate fluid resuscitation. (Strong recommendation) We propose considering the use of synthetic colloid solutions containing gelatin when hemodynamic goals of fluid resuscitation have not been achieved or are not being achieved using crystalloid solutions and when a fluid deficit persists. (Weak recommendation) Until the source of bleeding is controlled, we recommend aiming for a systolic blood pressure in a range of 80-90 mmHg in patients with PPH. (Strong recommendation) We recommend the use of vasopressors as soon as possible in PPH when target arterial blood pressure values cannot be reached by ongoing fluid resuscitation. (Strong recommendation) We recommend cooperation with a hematologist in the diagnosis and treatment of coagulopathy in PPH unresponsive to standard therapies. (Good Clinical Practice) In addition to the above-mentioned panel laboratory tests (at least KO, aPTT, fibrinogen), we also recommend using viscoelastic methods (ROTEM, TEG) to identify the type of coagulation disorder in PPH, to monitor it and for targeted treatment of hemostasis disorders. (Strong recommendation) To achieve/restore the efficacy of endogenous hemostatic mechanisms and coagulation support therapies, we recommend the maximum possible correction of hypothermia, acidosis and ionized calcium levels. (Strong recommendation) Early initiation of all available procedures to prevent hypothermia and maintain or achieve normothermia is recommended. (Strong recommendation) It is recommended monitoring and maintaining ionized calcium levels within the normal range when administering transfusion products. Preferably, calcium chloride should be administered for correction. (Strong recommendation) Fibrinogen replacement is recommended in patients with PPH when fibrinogen levels fall to < 2 g/L and/or when there is a functional fibrinogen deficiency detected by viscoelastic methods and/or when there is a reasonable clinical assumption of fibrinogen deficiency even without knowledge of fibrinogen levels. We recommend a minimum of 4 g of fibrinogen as an initial dose in PPH. (Strong recommendation) It is recommended to administer tranexamic acid (TXA) at an initial dose of 1 g i.v. as soon as possible after the onset of PPH. An identical dose may be repeated (after 30 min at the earliest) if bleeding continues and if hyperfibrinolysis is demonstrated and/or if hyperfibrinolysis is highly likely in the current clinical context. (Strong recommendation) We do not recommend further administration of TXA in patients with PPH after bleeding control has been achieved. (Strong recommendation) We recommend administration of plasma at a dose of 15-20 mL/kg in PPH conditions where coagulopathy of a different etiology than fibrinogen deficiency is suspected and/or abnormal coagulation test results are present, and where the results do not reliably identify the predominant mechanism of the coagulation disorder and its targeted correction. (Strong recommendation) We recommend the administration of prothrombin complex factors (PCC) in patients with PPH where there is a laboratory evidence of a deficiency of PCC factors. We do not recommend routine administration of PCC in patients with PPH. (Strong recommendation) We suggest considering administration of rFVIIa before making a decision on an endovascular or a surgical intervention. (Weak recommendation) In patients with PPH, we recommend administration of erythrocyte blood products to achieve a target hemoglobin value in the range 70-80 g/L. (Strong recommendation) In patients with PPH, we recommend platelet administration to achieve a target value of at least 50 × 109/L and/or when platelet function impairment is suspected or demonstrated. (Strong recommendation) We do not recommend routine measurement of antithrombin III levels in patients with PPH. (Strong recommendation) We do not recommend routine antithrombin III replacement in patients with PPH. (Strong recommendation) We recommend initiating pharmacological prophylaxis for thromboembolic disease as soon as possible after control of the source of PPH is achieved. We recommend initiating mechanical thromboprophylaxis (intermittent pneumatic compression or elastic stockings) as soon as the clinical condition permits. (Strong recommendation).
参考来源
- Černý V, Pařízek A, Bláha J, et al. Diagnosis and treatment of peripartum haemorrhage, consensus of the interdisciplinary working group by the modified ACCORD method. Ceska Gynekol. 2025. PMID: 40117262. doi:10.48095/cccg202572
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。